rewirebio.iobenchmarks
Method

HER2 expression (ERBB2 mRNA)

Uses ERBB2 gene expression, log2(1 + TPM), directly as the response score.

2 evaluations · 2 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for HER2 expression (ERBB2 mRNA). Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluated Checkpoint: As described in the Ladon technical report

Evaluations and results

2 evaluations · 2 results. Different protocols are not a single leaderboard.

Protocol: Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO

Sorted by AUROC (AUC for pathological complete response, HER2+ tumours, model fitted on TransNEO and applied unchanged) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationProtocol and datasetAUROC (AUC for pathological complete response, HER2+ tumours, model fitted on TransNEO and applied unchanged)
HER2 expression (ERBB2 mRNA)EvaluationPBCP HER2+ patients (18, 11 pCR)0.71 (best in column)
HER2 expression (ERBB2 mRNA)EvaluationDFCI inflammatory breast cancer HER2+ patients (22, 9 pCR)0.53
All 2 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Method: HER2 expression (ERBB2 mRNA)Protocol: Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO
Dataset subset: DFCI inflammatory breast cancer HER2+ patients (22, 9 pCR)
0.53 AUROC (AUC for pathological complete response, HER2+ tumours, model fitted on TransNEO and applied unchanged)
unitless · higher

Uncertainty: 95% CI 0.26 to 0.78. Percentile bootstrap resampling the cohort's patients; resamples with a single class discarded (page 39).

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

HER2 expression, DFCI IBC HER2+, pCR AUC

ladon-20261115-protocol-pcr-her2-pos-auc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 18 (page 35), panel 'HER2+' cohort 'DFCI IBC', row 'HER2 expression', column 'AUC [95% CI]'
Method: HER2 expression (ERBB2 mRNA)Protocol: Breast cancer pCR, HER2+ external cohorts, AUC of a model fitted on TransNEO
Dataset subset: PBCP HER2+ patients (18, 11 pCR)
0.71 AUROC (AUC for pathological complete response, HER2+ tumours, model fitted on TransNEO and applied unchanged)
unitless · higher

Uncertainty: 95% CI 0.41 to 0.96. Percentile bootstrap resampling the cohort's patients; resamples with a single class discarded (page 39).

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

HER2 expression, PBCP HER2+, pCR AUC

ladon-20261115-protocol-pcr-her2-pos-auc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 18 (page 35), panel 'HER2+' cohort 'PBCP', row 'HER2 expression', column 'AUC [95% CI]'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this method

How it works, versions and access

Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this method. Consult the linked sources and evaluation records below.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ladon-20261115-method-erbb2-expression.

Source locator: Page 40, Methods 'Other baselines'; Figure 18 caption

Related records

How to cite

HER2 expression (ERBB2 mRNA). Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/method/ladon-20261115-method-erbb2-expression/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction